GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regen BioPharma Inc (OTCPK:RGBP) » Definitions » Shiller PE Ratio

Regen BioPharma (Regen BioPharma) Shiller PE Ratio : (As of May. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regen BioPharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regen BioPharma Shiller PE Ratio Historical Data

The historical data trend for Regen BioPharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regen BioPharma Shiller PE Ratio Chart

Regen BioPharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regen BioPharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regen BioPharma's Shiller PE Ratio

For the Biotechnology subindustry, Regen BioPharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regen BioPharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regen BioPharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regen BioPharma's Shiller PE Ratio falls into.



Regen BioPharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regen BioPharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Regen BioPharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.03/129.4194*129.4194
=-0.030

Current CPI (Mar. 2024) = 129.4194.

Regen BioPharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -4.798 100.560 -6.175
201409 -5.624 100.428 -7.248
201412 -6.300 99.070 -8.230
201503 -13.200 99.621 -17.148
201506 -11.280 100.684 -14.499
201509 -5.850 100.392 -7.542
201512 -8.850 99.792 -11.477
201603 -8.700 100.470 -11.207
201606 -11.700 101.688 -14.891
201609 -10.800 101.861 -13.722
201612 -5.850 101.863 -7.433
201703 -13.950 102.862 -17.552
201706 -28.500 103.349 -35.689
201709 -14.550 104.136 -18.083
201712 -29.250 104.011 -36.395
201803 -11.700 105.290 -14.381
201806 -1.050 106.317 -1.278
201809 -8.700 106.507 -10.572
201812 1.050 105.998 1.282
201903 -1.650 107.251 -1.991
201906 -77.100 108.070 -92.332
201909 4.693 108.329 5.607
201912 4.500 108.420 5.372
202003 -3.900 108.902 -4.635
202006 2.400 108.767 2.856
202009 1.050 109.815 1.237
202012 1.175 109.897 1.384
202103 0.300 111.754 0.347
202106 -3.150 114.631 -3.556
202109 -0.375 115.734 -0.419
202112 1.500 117.630 1.650
202203 -22.040 121.301 -23.515
202206 19.110 125.017 19.783
202209 -0.010 125.227 -0.010
202212 0.450 125.222 0.465
202303 -0.030 127.348 -0.030
202306 -0.030 128.729 -0.030
202309 -0.100 129.860 -0.100
202312 -0.100 129.419 -0.100
202403 -0.030 129.419 -0.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regen BioPharma  (OTCPK:RGBP) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regen BioPharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regen BioPharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regen BioPharma (Regen BioPharma) Business Description

Traded in Other Exchanges
Address
4700 Spring Street, Suite 304, La Mesa, CA, USA, 91942
Regen BioPharma Inc is a US-based biotechnology company. It focuses on the development of regenerative medical applications in the stem cell space. The company's principal products and services include HemaXellarate I, HemaXellerate II, dCell Vax, NR2F6, Tcellvax, identification of Small Molecules, and others. HemaXellarate I and HemaXellerate II is a cellular therapy designed to heal damaged bone marrow. dCell Vax is a therapy whereby dendritic cells of the cancer patient are harvested from the body. Tcellvax is an autologous cellular product comprised of NR2F6 gene-silenced peripheral blood mononuclear cells.